ABSTRACT
Background The anterior cruciate ligament (ACL) is a commonly injured ligament in the knee. Bone tunnel widening is a known phenomenon after soft-tissue ACL reconstruction and etiology and clinical relevance have not been fully elucidated. Osteoconductive compounds are biomaterials providing an appropriate scaffold for bone formation such as demineralized bone matrix. Osteoinductive materials contain growth factors stimulating bone lineage cells and bone growth. A possible application of osteoinductive/osteoconductive (OIC) material is in ACL surgery.
Questions/Purposes We hypothesized that OIC placed in ACL bone tunnels: 1) reduces tunnel widening, 2) improves graft maturation and 3) reduces tunnel ganglion cyst formation. To test this hypothesis, this study evaluated the osteogenic effects of demineralized bone matrix (DBM) and platelet rich plasma (PRP) on tunnel widening, graft maturation, and ganglion cyst formation.
Study Design Randomized controlled clinical trial pilot study.
Methods A total of 26 patients electing ACL reconstruction surgery were randomized between OIC and control group. Measurements of tunnel expansion and graft-tunnel incorporation were conducted via quantitative image analysis of MRI scans performed at six months after surgery for both groups.
Results No patients had adverse post-operative reactions or infections. The use of OIC significantly reduced tunnel widening (p < 0.05) and improved graft maturation (p < 0.05). Patients treated with OIC presented with a significantly lower prevalence of ganglion cyst compared to the control group (p < 0.05).
Conclusion The use of OIC has measurable effects on the reduction of tunnel widening, improved graft maturation and decreased size of ganglion cyst after ACL reconstruction.
Clinical Relevance This study explored the utilization of biologics to minimize bone tunnel widening in ACL reconstruction surgery.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ClinicalTrials.gov Identifier: NCT04993339
Funding Statement
The project described was supported by Grant Number GR004579 from Arthrex, Inc (www.arthrex.com) awarded to FT. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
this study was approved by the IRB of the University of Miami (IRB ID:20150981). Patient enrollment was conducted via written consent form.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Footnotes
Funding The project described was supported by Grant Number GR004579 from Arthrex, Inc.
This study was registered at clinicaltrials.gov NCT04993339
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
